Brief: Tscan Therapeutics Completes Enrollment In Cohort C Of Phase 1 Alloha™ Trial
26/02/2026 12:20
Feb 26 (Reuters) - TScan Therapeutics Inc TCRX.O: TSCAN THERAPEUTICS COMPLETES ENROLLMENT IN COHORT C OF PHASE 1 ALLOHA™ TRIAL AND ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATIONS FOR HEME CANDIDATES TSC-102-A01 AND TSC-102-A03 TSCAN THERAPEUTICS INC: PLANS TO INITIATE PHASE 1 STUDY OF BOTH TSC-102 CANDIDATES IN SECOND HALF OF 2026 Source text: ID:nGNX9cJ90R Further company coverage: TCRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tscan Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Broadcom, Deere & Co, Snowflake
U.S. STOCKS ON THE MOVE-FuelCell, Gold miners, NetApp
U.S. STOCKS ON THE MOVE-AEVEX, Sirius XM, PG&E
U.S. STOCKS ON THE MOVE-TScan Therapeutics, EOS Energy, Brown-Forman Corp
Brief: TScan Therapeutics - Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics - SEC Filing